FDA Approved: KAZANO — Original Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved KAZANO, a fixed-dose combination of alogliptin and metformin hydrochloride, as a new product for managing type 2 diabetes mellitus. This origin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• KAZANO (alogliptin and metformin hydrochloride)

Snippet

ORIG AP for KAZANO (ALOGLIPTIN AND METFORMIN HYDROCHLORIDE)